Ruiqiao Dingke Group and Cosmotec Announce Landmark Strategic Partnership for Japanese Market

Source: Global Times

On September 15, EverBridge Group announced an exclusive commercialization partnership with Cosmotec Co., Ltd., a wholly-owned subsidiary of M3, Inc., a globally renowned provider of medical information services, for the Japanese market. Leveraging the M3 platform and Cosmotec’s localized commercial expertise, both parties will promote the implementation and widespread adoption of EverBridge’s advanced therapeutic solutions in Japan.

This strategic partnership fully demonstrates EverBridge Group’s leadership advantages in independent R&D, compliance management, and value-driven ecosystem collaboration, marking a significant step forward in the company’s globalization strategy and further enhancing its influence in the international market. Meanwhile, the collaboration also highlights the strengths of Cosmotec’s leading digital commercial platform, which accelerates market access for international medical devices and enables precise engagement with end-user clinicians.

Takumi Odomi, CEO of Cosmotec, stated: “The product portfolio under the EverBridge Group demonstrates excellence in clinical efficacy and human-centered design, perfectly aligning with Japanese physicians’ pursuit of advanced therapeutic solutions. By integrating the M3 academic platform with our localized commercial expertise, we will undoubtedly accelerate the adoption and promotion of these devices across the Japanese market.”

Wang Jian, CEO of EverBridge Group, stated, “Cosmotec’s digital business model combines efficiency with accessibility, aligning closely with our vision to advance equitable medical innovation. This collaboration not only enables us to navigate Japan’s stringent technical regulatory landscape and deliver transformative solutions to patients, but also deepens global R&D synergy. Reducing barriers to advanced healthcare through innovation and ecosystem collaboration remains the core mission of our globalization strategy.”

With the in-depth advancement of the “Healthy China 2030” strategy and the continuous growth of global healthcare demand, EverBridge Group has been deeply implementing its “bring in, go global” internationalization strategy, marking a leap for Chinese medical device enterprises from “product export” to “value export.” EverBridge Group will continue to anchor itself in robust technological innovation, leverage compliant lean operations and brand building as its two wings, and break through resource constraints by constructing an ecosystem of partnerships, thereby contributing significant strength to global medical innovation.